Each year, the International Congress of Parkinson's Disease and Movement Disorders brings together thousands of clinicians, researchers and members of industry to share scientific updates and the latest research progress in the field. This year, the event is taking place virtually.

From September 12 through 16, the virtual Congress will offer educational content, skills workshops, poster halls and access to selected abstracts. The Michael J. Fox Foundation for Parkinson’s Research (MJFF) will be featured in the Non-Profit Partners section of the virtual platform for registrants and we will be at booth #997 at the exhibit hall — make sure to stop by to connect with our staff.

Throughout five days, the virtual Congress will feature MJFF grantees, partners, advisors and data from sponsored studies. Our guide to the program follows:

• Saturday, September 12, 8 to 10 a.m. ET, Therapeutic Plenary Session 101. Updates on Medical Management Strategies for Parkinson’s Disease: Motor Aspects. Alice Nieuwboer et al.
• Saturday, September 12, 10:30 a.m. to 12:30 p.m. ET, Therapeutic Plenary Session 102. Parkinson’s Disease: Non-Motor Aspects. Ron Postuma et al.
• Sunday, September 13, 2 to 3:30 p.m. ET, Skills Workshop 503. Imaging in Parkinson’s Disease. Marios Politis et al.
• Monday, September 14, 8 to 10 a.m. ET, Plenary Session 203. Parkinson’s Disease Biomarkers: A Multidisciplinary Approach. Brit Mollenhauer et al.
• Monday, September 14, 10:30 a.m. to 12:30 p.m. ET, Parallel Session 309. Update on Recent Clinical Trials. Tatyana Simuni et al. (And look out for a segment from Meredith Bock, MD, a movement disorders fellow at the University of California, San Francisco, whose analysis using data in Fox DEN was selected as a top abstract.)
• Monday, September 14, 2 to 3:30 p.m. ET, Special Topics in Movement Disorders 604. Setting Up Your Telemedicine Clinic. Piu Chan et al.
• Tuesday, September 15, 10:30 a.m. to 12:30 p.m. ET, Parallel Session 317. Gene-driven Therapies Under Development for Parkinson’s Disease. Elisa Greggio et al.
• Tuesday, September 15, 10:30 a.m. to 12:30 p.m. ET, Teaching Course 405. Parkinson’s Disease Biomarkers. Alice Chen-Plotkin et al.
• Tuesday, September 15, 10:30 a.m. to 12:30 p.m. ET, Science of Industry Session 902. Immunotherapy for Proteinopathies. Gennaro Pagano will discuss PASADENA phase II study results.
• Wednesday, September 16, 8 to 10 a.m. ET, Plenary Session 206. Translational Insights into New Parkinson’s Disease-Modifying Therapies. Malú Tansey et al.
• Wednesday, September 16, 10:30 a.m. to 12:30 p.m. ET, Plenary Session 208. Highlights from 2020: Looking Toward 2021. Claudia Trenkwalder et al.

And check out the Guided Poster Tours section of the virtual platform, which features a presentation from biotech company AFFiRiS on results from their phase I study testing PD01A, an experimental vaccine to treat Parkinson's.

To learn more or register, visit mdscongress.org.